Mylan Pharmaceuticals has announced the launch of the Wixela Inhub fluticasone propionate/salmeterol DPI in Canada. According to the company, Health Canada approved Wixela Inhub, a generic version of Advair Diskus, in January 2020 for asthma and COPD. The inhaler will be available in 100 mcg/50 mcg, 250 mcg/50 mcg, and 500 mcg/50 mcg strengths for asthma and 250 mcg/50 mcg and 500 mcg/50 mcg strengths for COPD.
In the US, the FDA approved Wixela Inhub in January 2019, and Mylan launched the inhaler in February 2019.
Mylan Canada Country Manager David Simpson said, “We’re pleased to offer Wixela Inhub as the first available bioequivalent alternative to Advair Diskus, one of the leading treatments for asthma and COPD management today. Wixela Inhub is the result of a $700M investment worldwide, including an extensive research and development program. With today’s launch in Canada, we are pleased to expand access to this important medicine by providing a more affordable alternative to appropriate asthma and COPD patients.”
Read the Mylan press release.
